Amiloride (MK-870): Epithelial Sodium Channel Inhibitor for Ion Channel Research

Executive Summary: Amiloride (MK-870) is a potent inhibitor of epithelial sodium channels (ENaC) and urokinase-type plasminogen activator receptors (uPAR), used as a research tool for dissecting sodium channel and receptor-mediated signaling pathways (APExBIO). It selectively blocks PC2 channels, enabling modulation of ion transport and endocytosis mechanisms in cell models. Peer-reviewed inhibitor analyses confirm its specificity and show that it does not universally block all forms of endocytosis in aquatic or mammalian systems (Wang et al. 2018). Amiloride (MK-870) is supplied as a solid reagent, with a molecular weight of 229.63 g/mol and formula C6H8ClN7O, optimized for research use only. Proper storage at -20°C and prompt use of prepared solutions are essential for reproducibility and compound integrity (APExBIO).

Biological Rationale

Amiloride (MK-870) was developed to target epithelial sodium channels (ENaC), which are central regulators of sodium balance and fluid homeostasis in epithelial tissues. ENaC dysfunction is implicated in diseases such as cystic fibrosis and hypertension (see this mechanistic review; this article provides new experimental specificity data). The compound also inhibits uPAR, a receptor involved in cellular migration, endocytosis, and tissue remodeling. Blocking ENaC or uPAR-mediated pathways allows researchers to dissect the roles of sodium flux and receptor signaling in disease models and basic cell biology. Amiloride (MK-870) is widely used to benchmark sodium transport assays, validate receptor-mediated uptake, and interrogate mechanisms of epithelial and endothelial permeability. Its specificity makes it valuable in studies that require precise mechanistic dissection of ion channel and receptor functions.

Mechanism of Action of Amiloride (MK-870)

Amiloride (MK-870) acts primarily as a competitive inhibitor of ENaC, binding to the extracellular domain and blocking sodium ion influx through the channel. It is also a blocker of the PC2 (polycystin-2) channel and inhibits the urokinase-type plasminogen activator receptor (uPAR) pathway. By inhibiting ENaC, it reduces sodium reabsorption in epithelial cells, thereby modulating downstream effects on osmotic balance and cell signaling. Its action on uPAR impedes uPA-mediated cell migration and endocytosis, affecting processes such as wound healing and tumor invasion (see this application guide; this article provides evidence-based claims on specificity and boundaries). Amiloride's dual mechanism enables researchers to examine both ion transport and receptor-mediated events in a variety of models.

Evidence & Benchmarks

• Amiloride (MK-870) inhibits ENaC-mediated sodium transport in mammalian epithelial cells at micromolar concentrations (1–10 μM) under physiological pH and temperature (37°C) conditions (Wang et al. 2018).
• In grass carp kidney (CIK) cell viral entry assays, Amiloride did not inhibit clathrin-mediated endocytosis of GCRV104, indicating mechanistic selectivity and boundary conditions for endocytosis modulation (Wang et al. 2018).
• Amiloride (MK-870) is stable as a solid at -20°C, but aqueous solutions should be used promptly and are not recommended for long-term storage (APExBIO).
• APExBIO's Amiloride (BA2768) is validated as a research-only reagent and is not suitable for diagnostic or therapeutic use (APExBIO).
• Recent benchmarking confirms that Amiloride (MK-870) selectively inhibits ENaC without affecting unrelated endocytosis pathways in non-epithelial cell models (internal benchmark update).

Applications, Limits & Misconceptions

Amiloride (MK-870) is applied in studies of:

• Sodium channel function and regulation in epithelial and endothelial tissues.
• Cellular uptake and endocytosis modulation, primarily in ENaC- and uPAR-expressing cells.
• Translational research models for hypertension, cystic fibrosis, and tissue injury.
• Mechanistic dissection of receptor-mediated pathways related to cell migration and tissue remodeling.

However, several boundaries and misconceptions exist regarding its use:

Common Pitfalls or Misconceptions

• Amiloride does not universally block all forms of endocytosis; it is ineffective against clathrin-mediated viral entry in certain aquatic cell models (Wang et al. 2018).
• It is not suitable for diagnostic or clinical use; for research applications only (APExBIO).
• Aqueous solutions of Amiloride (MK-870) degrade rapidly and must be used immediately after preparation; long-term storage leads to loss of potency.
• It does not inhibit all sodium transporters; its action is selective for ENaC and related channels.
• Its effectiveness depends on cell type, expression of target channels/receptors, and precise experimental conditions (e.g., buffer, temperature, pH).

This article updates and clarifies boundaries set in this prior application-focused summary, by adding new evidence from aquatic model systems and cross-platform comparisons.

Workflow Integration & Parameters

Integration of Amiloride (MK-870) into research workflows requires careful attention to concentration, timing, and storage:

• Dissolve Amiloride (MK-870) in DMSO or aqueous buffer immediately before use; typical working concentrations range from 1–100 μM.
• Store solid at -20°C; ship with Blue Ice for small molecules. Avoid repeated freeze/thaw cycles.
• Do not store aqueous solutions for extended periods; prepare fresh for each experiment to ensure activity (APExBIO).
• Use appropriate negative and positive controls to distinguish ENaC/uPAR-dependent effects from off-target phenomena.
• Report all environmental parameters (temperature, buffer composition, time, cell line) for reproducibility.

Comparative guides such as this lab-focused Q&A offer protocol advice and troubleshooting, but the present article provides expanded mechanistic boundaries and recent cross-species benchmarks.

Conclusion & Outlook

Amiloride (MK-870) (APExBIO, BA2768) remains a gold-standard tool for precise inhibition of epithelial sodium channels and uPAR in cellular research. Its mechanistic specificity and well-characterized boundaries allow for targeted investigation of ion transport, receptor signaling, and cellular uptake. Researchers are advised to integrate the latest evidence on mechanistic specificity and storage requirements to maximize reproducibility. Future directions include expanded benchmarking in disease-relevant models (e.g., cystic fibrosis, hypertension) and integration with advanced imaging or omics approaches to further dissect ENaC/uPAR-dependent signaling networks.